• Javier Soto, Carlos Rodriguez-Antolin, Elena Vallespín, de Castro CarpeñoJavierJBiomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain., and Inmaculada Ibanez de Caceres.
• Cancer Epigenetics Laboratory, INGEMM, La Paz University Hospital, Madrid, Spain; Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Madrid, Spain.
• Transl Res. 2016 Mar 1; 169: 1-18.e1.

AbstractEpigenetics is currently in an exponential phase of growth, constituting one of the most promising fields in science, particularly in cancer research. Impaired epigenetic processes can lead to abnormal gene activity or inactivity, causing cellular disorders that are closely associated with tumor initiation and progression. Thus, there is a pivotal role of massive sequencing techniques for epigenetics, which aim to find novel biomarkers, factors of prognosis and prediction, and targets for achieving personalized treatments. We present a brief description of the evolution of next-generation sequencing technologies and its coupling with DNA methylation analysis techniques, highlighting its future in translational medicine and presenting significant findings in several malignancies. We also expose critical topics related to the implementation of these approaches, which is expected to be affordable for most research centers in the near future. Copyright © 2016 Elsevier Inc. All rights reserved.

10 keywords...

hide…